11 recruiting, 6 completed, 3 terminated, 2 withdrawn. 6 Phase 2, 5 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Terminated 2, Unknown 1 |
| Not applicable | 5 | Recruiting 2, Withdrawn 2, Completed 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Oncology Institute of Southern Switzerland: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of a Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surgery Music therapy intervention - Lung Cancer (Suspected or Confirmed) | Not applicable | Recruiting | Oncology Institute of Southern Switzerland | 74 | 2026-06-19 | 2026-07-08 |
| LUCINAE Registry: Thoracic Cancers During Pregnancy Lung Cancer, Thoracic Cancer | Recruiting | Oncology Institute of Southern Switzerland | 100 | 2026-04-23 | 2026-10-21 | |
| Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer Compartmentalized Postoperative Radiotherapy - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Olgun Elicin | 50 | 2026-01-15 | 2026-08-27 |
| Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer SX-682, Apalutamide - Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 78 | 2025-04-28 | 2026-09-08 |
| Lifestyle Intervention in Patients With Metastatic Prostate Cancer Lifestyle intervention - Prostate Cancer | Not applicable | Recruiting | Oncology Institute of Southern Switzerland | 30 | 2023-11-27 | 2025-11-18 |
| Metronidazole as Preoperative Therapy in CRC / FusoMetro-001 Metronidazole Oral - Colorectal Cancer | Phase 2 | Recruiting | Oncology Institute of Southern Switzerland | 40 | 2023-09-11 | 2025-11-18 |
| The Immune Landscape of Epithelial Ovarian Cancer Collection of tumor samples, blood and vaginal and rectal swabs - Epithelial Ovarian Cancer | Recruiting | Oncology Institute of Southern Switzerland | 74 | 2022-12-20 | 2025-11-18 | |
| Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis. Jalosome soothing gel - Radiodermatitis, Oncology | Not applicable | Withdrawn | Welcare Industries SpA | 2021-02-01 | 2022-02-08 | |
| Tumor Molecular Profiling in Early Phase Clinical Trials Advanced Solid Tumor, Lymphoma | Recruiting | Oncology Institute of Southern Switzerland | 40 | 2020-10-01 | 2025-11-18 | |
| Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC Atezolizumab - NSCLC Stage IV | Phase 2 | Terminated | Oncology Institute of Southern Switzerland | 12 | 2020-10-01 | 2025-11-18 |
| Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer polysomnography, actigraphy, questionnaires - Prostate Cancer, Breast Cancer | Recruiting | Oncology Institute of Southern Switzerland | 60 | 2020-09-24 | 2025-11-18 | |
| Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients Cardiac MRI - Cardiotoxicity | Completed | Oncology Institute of Southern Switzerland | 150 | 2020-09-15 | 2025-11-18 | |
| Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1 Enzalutamide - COVID-19 Infection | Phase 2 | Terminated | Ricardo Pereira Mestre | 7 | 2020-08-24 | 2022-08-10 |
| Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19 Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml - COVID-19, Pulmonary Embolism, Deep Vein Thrombosis | Phase 3 | Terminated | University of Zurich | 475 | 2020-06-15 | 2022-05-25 |
| Prevalence of Wild Type ATTR HE and Congo red staining - Wild-type Transthyretin Amyloidosis | Completed | Oncology Institute of Southern Switzerland | 94 | 2019-11-01 | 2023-03-27 | |
| Personalized Risk Stratification Model of Follicular Lymphoma Patients Follicular Lymphoma | Active not recruiting | Oncology Institute of Southern Switzerland | 370 | 2018-03-01 | 2025-11-18 | |
| A Prognostic Tool for Early Stage CLL Chronic Lymphocytic Leukemia | Completed | Oncology Institute of Southern Switzerland | 4933 | 2018-03-01 | 2021-09-16 | |
| Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients biological samples collection and analysis - Prostate Cancer | Recruiting | Oncology Institute of Southern Switzerland | 600 | 2017-12-15 | 2025-11-18 | |
| Liquid Biopsy in Mature B-cell Tumors Liquid Biopsy - Mature B-Cell Neoplasm | Recruiting | Oncology Institute of Southern Switzerland | 444 | 2017-09-01 | 2026-07-09 | |
| Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells Ruxolitinib 20 MG - Prostate Cancer | Not applicable | Withdrawn | Oncology Institute of Southern Switzerland | 2017-09-01 | 2025-11-18 |
Showing 20 of 24. Sign in to see all of them.
Prostatic Neoplasms (6) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Follicular (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · COVID-19 (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Ovarian Epithelial (2) · Lung Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Neoplasms (2) · Pain (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma, Follicular (1)
Actigraphy (1) · Blood Specimen Collection (1) · Echocardiography (1) · Enoxaparin (1) · Indinavir (1) · Liquid Biopsy (1) · Metronidazole (1) · Polysomnography (1) · Radiotherapy (1) · Ritonavir (1) · Surveys and Questionnaires (1) · apalutamide (1) · atezolizumab (1) · enzalutamide (1) · ibrutinib (1)
Switzerland (22) · Italy (3) · Germany (1) · United Kingdom (1)
Davide Rossi, MD, PhD (4) · Adalgisa Condoluci, MD (1) · Andrea Alimonti, Prof. (1) · Francesco Martucci, MD (1) · Gianfranco A Pesce, MD (1) · Ilaria Colombo, MD (1) · Ilja Ciernik, MD (1) · Luca Giovanella, MD (1) · Nils Kucher, Prof. (1) · Professor Johann de Bono, MB ChB, FRCP, MSc, PhD, FMedSc (1) · Ricardo Pereira Mestre, MD (1) · Timo Nannen (1)
PMID 32267500, PMID 32907635, PMID 35451989, PMID 35779558, PMID 37591523
2019 (1)